


MAIN Ser CISTI/ICIST NRC/CNRC
RC254 MAIN Ser
.A1 1019-6439
I61 Received on: 12-23-99
v. 16 International Journal of
no. 1 oncology.
Jan 2000


International Journal of Oncology



ISSN 1019-6439

An international journal devoted to Oncology Research and Cancer Treatment

VOLUME 16, NUMBER 1, JANUARY 2000




Norm to 20%	20% O2	20% O2 + 10-6 GTN	20% O2 + 10-10 GTN	1% 1% O2 + 10-6 GTN	1% O2 + 10-10 GTN	
	0.780488	1.510125101	1.156691567	2.902439	1.078429179	2.88740048
	1	1.47799478	1.028170282	3.065497	0.978574625	2.977631745
	1.02439	1.124561246	0.931779318	2.902439	1.09840009	2.075319095
	0.934426	0.683619995	0.503146956	3.64708	2.184494373	2.636490047
	1.065574	0.665143779	0.462895199	3.606557	2.034578093	2.616364169
		0.665143779	0.442769321	3.606557	1.906078424	2.797497073
				3.079757		
				2.937926		
				3.100018		

Median	1	0.90409062	0.717463137	3.079757	1.502239257	2.71699356
1q	0.934426	0.669762833	0.472958138	2.937926	1.083421906	2.621395638
3q	1.02439	1.389636396	1.004072541	3.606557	2.002453175	2.864924628
plus	0.02439	0.485545776	0.286609404	0.526801	0.500213919	0.147931069
minus	0.065574	0.234327788	0.244504998	0.141831	0.41881735	0.095597922
percent	78.04878	151.0125101	115.6691567	290.2439	107.8429179	288.740048
	100	147.799478	102.8170282	306.5497	97.85746252	297.7631745
	102.439	112.4561246	93.17793178	290.2439	109.840009	207.5319095
	93.44262	68.36199946	50.31469555	364.708	218.4494373	263.6490047
	106.5574	66.51437786	46.28951991	360.6557	203.4578093	261.6364169
		66.51437786	44.27693208	360.6557	190.6078424	279.7497073
				307.9757		
				293.7926		
				310.0018		

	20% O2	20% O2 + 10-6 GTN	20% O2 + 10-10 GTN	1% 1% O2 + 10-6 GTN	1% O2 + 10-10 GTN	
Median	100	90.40906201	71.74631366	307.9757	150.2239257	271.699356
1q	93.44262	66.97628326	47.29581382	293.7926	108.3421906	262.1395638
3q	102.439	138.9636396	100.4072541	360.6557	200.2453175	286.4924628
plus	2.439024	48.55457762	28.66094041	52.68005	50.02139189	14.79310686
minus	6.557377	23.43277875	24.45049985	14.18309	41.88173502	9.559792155

	20% O2	20% O2 + 10-10 GTN	20% O2 + 10-6 GTN	1% 1% O2 + 10-10 GTN	1% O2 + 10-6 GTN
Median	100	71.74631366	90.40906201	307.9757	271.699356
1q	93.44262	47.29581382	66.97628326	293.7926	262.1395638
3q	102.439	100.4072541	138.9636396	360.6557	286.4924628
plus	2.439024	28.66094041	48.55457762	52.68005	14.79310686
minus	6.557377	24.45049985	23.43277875	14.18309	9.559792155



36
0.173913043

20% O₂, 25 μm, 10⁻¹⁰ GTN

189
7

hypoxic, 0 μm, 0 GTN

103
7

hypoxic, 25 μm, 0 GTN

127
4

hypoxic, 0 μm, 10⁻⁶ GTN

127
4

hypoxic, 25 μm, 10⁻⁶ GTN

90
4

hypoxic, 0 μm, 10⁻¹⁰ GTN

143
4

hypoxic, 25 μm, 10⁻¹⁰ GTN

108
4

date #	[O ₂]	[adr]	[GTN]	[cell]
#1	20% O ₂	0	0	5x10 ⁻²
	1%	0	0	5x10 ⁻²
#2	20	25	0	
	1	25	0	
#3	20	0	10 ⁻⁶	
	1	0	10 ⁻⁶	
			10 ⁻⁶	
			10 ⁻⁶	

Set up MDA-MB-231 cells for Experiment
 19990917 - Adr. hypoxia - colony assay
 grow in RPMI + 5% FBS + P/S
 - cell density for experiment looked good
 - changed media on plates - 150mm received 15ml
 - 100mm received 7ml
 placed in 20% O₂ incubator and hypoxic
 chamber (11:20)
 adriamycin dilutions: stock conc. 2mg/ml
 1µM adm: 0.580 µg/ml mw = 580
 0.58 µg/ml = 0.29 µl in 1ml = 29 x 25ml = 7.25 µl
 25µM adm: 14.5 µg/ml
 = 36.25 µl of adm in 50ml
 50µM adm: 29 µg/ml
 = 72.5 µl of adm in 50ml
 100µM adm: 58 µg/ml
 = 145 µl of adm in 50ml
 - make up in RPMI + 5% FBS + P/S
 - remove plates of cells from chamber - 1% O₂
 (monitor reading)
 - removed media from plates and added
 fresh media to 0µM adm controls and
 adriamycin/media to appropriate plates.

For other drugs: [] from lit.

cyclophosphamide $12.5 \mu M \rightarrow 500 \mu M$ 0-100 μM
(Kobayashi et al., 1993)

methotrexate

$\rightarrow 25, 50, 100, 150, 200 \mu M$

cisplatin? 0-14 $\mu g/mL$

Counting: 1/10 exp't.

Plate	[dox]	[Co2]	# cells	# colonies	P.E	CF
#15	25 μM	20%	5×10^9	2	4×10^{-5}	6.93×10^{-5}
				1	2×10^{-5}	3.9×10^{-5}
				2	1×10^{-5}	6.73×10^{-5}
	17.		5×10^9	45	9×10^{-4}	2.31×10^{-3}
				24	4.8×10^{-4}	0.0018
				40	8×10^{-4}	0.00197

Next exp't.

	0 μM	25 μM
SNP	+ 5×10^3 + 10^3 + 5×10^2 + 10^2	+ 5×10^4 + 10^4 + 5×10^3 + 10^3
GTM	+	+
Control	-	-
Everything x2	17.	20%
	(One hypoxic, one normoxic)	
	\therefore 12 100mm plates.	

30mg in 10ml $10^{-2} M$

Not enough plates (p).

So: Set-up.

[dox]	1% O_2		20% O_2	
	0	25	0	25
control	✓	✓	✓	✓
SNP 10^{-6}	✓	✓	_____	_____
10^{-10}	✓	✓	_____	_____
GTN 10^{-6}	✓	✓	_____	_____
10^{-10}	✓	✓	_____	_____

① Put 2 normox plates in @ 37°C @ 115am

② Put plates in hypoxia @ 1135am

Remove media.

Add 7ml of either RPMI + P/S

or RPMI + P/S + approp [] of GTN or SNP.

CHECK PLATES FROM

on OM. colonies growing (v. small (shl))

strain 5×10^3 (will be confluent soon).

1 μM strain 5×10^3

* All media w/ adriamycin has to be treated w/ charcoal (so don't put into bleach)

Experiment w/ NO donor. Exp't

① look & out of hypoxic chamber @ 11am
37°C incubator

② Removed media and added 7 mL of

a) RPMI + FBS + P/S
or b) RPMI + FBS + P/S + adriamycin
↳ 25 μ M conc.

↳ put 25 μ M in incubator @ 11:30am

0.25 μ M in incubator @ 11:30am

⇒ 37°C, 20% O₂ for 1 hr
↳ take out @ 12:15 pm

③ Remove media from all plates *

add 2 mL trypsin/EDTA

• sit for ~ 5 min

③ Add 8 mL of media (RPMI + FBS + P/S)

• resuspend &

• put into 50 mL conicals

• count

[O ₂]	[dox]	[GTN]	count	#4/mL (#4 x 10 ⁴ x R)
20% O ₂	0	0	94/4	47 x 10 ⁴
20% O ₂	25	0	113/4	96.5 x 10 ⁴
20% O ₂	0	10 ⁻⁶	211/4	181.5 x 10 ⁴
20% O ₂	25	10 ⁻⁶	189/4	92 x 10 ⁴
20% O ₂	0	10 ⁻¹⁰	171/4	85.5 x 10 ⁴
20% O ₂	25	10 ⁻¹⁰	189/4	94.5 x 10 ⁴

experiments for Thursday

	0 μ M	25 μ M
SNP	+ 5×10^3 10 ³ 5×10^2 ✓ 10 ² ✓	+ 5×10^4 ✓ 10 ⁴ ✓ 5×10^3 10 ³

GTN

+

⊖

plates - set up 6x2-12 100mm plates

make up 50ml of adriamycin (25 μ M)
need 24, 6 well plates

Thursday exp cancelled - O₂ conc
16.4% - try again Tuesday

0 μ M

25 μ M

10⁻⁶ GTN
conc. 1

5×10^2 }
10² }

5×10^4 }
10⁴ }

10⁻⁷⁰ GTN
conc. 2

5×10^2
10²

5×10^4
10⁴

5×10^2
10²

5×10^4
10⁴

6x2
12 plates

original P/S

subculture cells

set up 12 plates for Monday

stained remaining plates from

experiment

plate #	μM	cell #
4	100	5×10^4
3	100	10^3
9	50	10^5
10	50	5×10^4

checked plates from

adr-hyp

experiment -

- adig-hyp - GTN

- cell counts

20% O_2 , 0 μM , 0 GTN

$$\frac{94 \times 10^4 \times 2}{42} = 47 \times 10^4 / \text{ml}$$

20% O_2 , 25 μM , 0 GTN

193

~~20% O_2~~ 4

20% O_2 , 0 μM , 10^{-6} GTN

259

4

20% O_2 , 25 μM , 10^{-6} GTN

184

4

20% O_2 , 0 μM , 10^{-10} GTN

171

4

The Effects of Nitric Oxide on the Urokinase System of Plasminogen Activation and on Cellular Invasiveness

425 Thesis

By: Lynne Postovit

Supervisor: Dr. C. Graham

ABSTRACT

Cellular invasion is a process which characterizes such biological occurrences as tumour progression and zygote implantation. It also plays a critical role in the remodelling of the uterine vasculature during the first trimester of pregnancy. Failure of trophoblast cells to complete this function may lead to such pathologies as pre-eclampsia. Both tumour progression and uterine remodelling have been shown to occur under low oxygen levels. The urokinase system of plasminogen activation plays a vital role in cellular invasiveness. Further, the expression of the urokinase-type plasminogen activator receptor (uPAR), as well as *in vitro* cellular invasion, increase under hypoxic conditions. In this study, immortalized human trophoblasts (HTR-8/SVneo cells) were used to study the effects of low levels of nitric oxide (NO) on uPAR expression and cellular invasion under hypoxic conditions. Exposure to the NO donors, sodium nitroprusside (SNP) and glyceryl trinitrate (GTN) resulted in a decrease in uPAR mRNA levels, as determined by Northern blot analysis. Further, they also decreased the ability of trophoblast cells to invade an extracellular matrix *in vitro*. These findings indicate that under hypoxic conditions, low levels of NO inhibit uPAR expression as well as *in vitro* cellular invasiveness. Through a similar mechanism, NO donors may be used therapeutically to inhibit tumour progression *in vivo*. Further, by inhibiting the invasiveness of trophoblast cells during the first trimester of gestation, NO may be playing an etiological role in the development of pre-eclampsia.

INTRODUCTION

Pre-eclampsia is a common pathology of human pregnancy, causing such problems as